Metrics to compare | ENVB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipENVBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.6x | −10.4x | −0.2x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price / Book | 1.1x | 1.8x | 2.6x | |
Price / LTM Sales | - | 1.8x | 2.7x | |
Upside (Analyst Target) | - | 120.0% | 72.2% | |
Fair Value Upside | Unlock | 1.7% | 12.4% | Unlock |
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.